compani updat chang price
includ revenu st initi
guidanc st vs st announc
new instrument call iseq serv low-throughput market
like entri point clinic custom pleas see detail
take continu digest announc
shock see share hour given investor focu
guid indic longev novaseq adopt cycl
come st expect believ revenu growth
estim highlight transform opportun novaseq bring
commun find commentari around clinic adopt
develop encourag market repres next leg
ilmn long-term growth additionali ilmn announc sever
new technolog includ iseq box nextera flex librari prep
partnership w/ develop ampliseq instrument
highlight compani hyperfocu penetr clinic market
democrat technolog custom base
believ immedi move share repres de-risk event
fear clinic opportun away
given develop rais pt reiter
outperform rate maintain top growth pick
preliminari revenu mm yoy
consensu mm evr mm
preliminari revenu bn yoy
consensu evr bn yoy
 driven strength novaseq clinic adopt consum
revenu guidanc bn yoy
consensu bn evr bn
ep guidanc consensu
in-lin w/ evr
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
introduc iseq
 owner outsourc new
 broad base custom exist core servic lab small batch test
 begin shipment
 similar desktop system
 size cost hiseq w/ faster throughput
 use liquid sampl
 product pcr librari wg faster increas output
 includ exom prep faster current method
partnership w/ ampliseq use instrument
 rapidli adopt oncolog space
 use ffpe tissu
 custom access algorithm on-line assay develop tool
 import entri point new-to-ng custom
ship w/ shipment high
 target custom adopt
shipment strong contributor growth
consum sequenti
continu import part penetr clinic market
new desktop convers account placement
continu expect multi-yr adopt cycl earli stage adopt
impact market
 larger cohort studi
 doubl capac expect sequenc sampl uk biobank end
 personali plan sequenc genom va biobank
 grail etc need sequenc higher depth clinic need
 broader swath genom
 mll genedx kingm dx clinic panel
shipment account bn cumul sale
consum genom inflect point mm sampl run mm sampl genotyp sequenc date
continu see strong growth china emerg market
receiv approv nextseqdx
million except per share data fy end decemb sequenc organ gp less op less ep share inc net inc price-to-earnings prem disc januari
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin januari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
